Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- AI Summary
- About
GNPX 
Genprex Inc (GNPX)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/14/2025: GNPX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -49.64% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.28M USD | Price to earnings Ratio - | 1Y Target Price 7.5 |
Price to earnings Ratio - | 1Y Target Price 7.5 | ||
Volume (30-day avg) 684780 | Beta -1.29 | 52 Weeks Range 0.28 - 13.00 | Updated Date 01/14/2025 |
52 Weeks Range 0.28 - 13.00 | Updated Date 01/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.69 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -145.94% | Return on Equity (TTM) -318.88% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4723459 | Price to Sales(TTM) - |
Enterprise Value 4723459 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.18 | Shares Outstanding 8508070 | Shares Floating 2424665 |
Shares Outstanding 8508070 | Shares Floating 2424665 | ||
Percent Insiders 6.4 | Percent Institutions 10.91 |
AI Summary
Genprex Inc. (GNPX): A Detailed Overview
Disclaimer: The information provided below is for informational purposes only and should not be considered investment advice. Investing involves risk, and you should carefully consider your own investment goals and risk tolerance before making any investment decisions.
Company Profile
History and Background: Founded in 1999, Genprex Inc. (GNPX) is a clinical-stage gene therapy company located in San Diego, California. The company focuses on developing and commercializing gene therapy technologies for the treatment of cancer and other diseases. Genprex utilizes its proprietary ONCOPREX® platform to deliver therapeutic genes directly into tumor cells, offering a potentially targeted and effective approach to cancer treatment.
Core Business Areas:
- Drug Development: Genprex focuses on developing innovative gene therapy products for various oncological and infectious diseases.
- Licensing and Partnerships: The company actively seeks partnerships and licensing agreements to expand its product portfolio and market reach.
- Contract Research Services: Genprex offers contract research services to other pharmaceutical and biotechnology companies in the areas of gene therapy and drug delivery.
Leadership Team and Corporate Structure:
- President and CEO: Rodney Varner, Ph.D.
- Chief Scientific Officer: Jae-Hyun Kim, Ph.D.
- Chief Financial Officer: Rodney Varner, Ph.D.
- Executive Vice President, Business Development: Robert J. Foster
- Board of Directors: Consists of experienced individuals with expertise in gene therapy, pharmaceuticals, finance, and law.
Top Products and Market Share
Top Products:
- Oncoprex® - Immunogene Therapy for Cancer: This platform delivers therapeutic genes directly into tumor cells, stimulating the immune system to attack and destroy the cancer cells. It is currently in Phase II clinical trials for the treatment of non-small cell lung cancer.
- Gene-Mediated Vaccines for Infectious Diseases: Genprex is developing gene-mediated vaccines for infectious diseases such as COVID-19 and HIV.
Market Share: Genprex is a relatively small player in the gene therapy market. As of November 2023, the company does not have any approved products on the market. However, its Oncoprex platform has the potential to be a significant competitor in the immunotherapy space if successful in clinical trials.
Product Performance and Market Reception: The Oncoprex platform has shown promising pre-clinical and early-stage clinical data. However, it is still in development, and its long-term efficacy and safety profile are not yet fully established. The market reception will depend on the success of the ongoing clinical trials and potential regulatory approvals.
Total Addressable Market
The global gene therapy market is estimated to be worth over $15 billion in 2023 and is projected to grow at a CAGR of over 20% in the coming years. The market for cancer immunotherapy is a significant segment within the gene therapy market and is expected to be a major driver of growth.
Financial Performance
Recent Financial Statements: Genprex is a pre-revenue company, and its recent financial statements reflect development-stage expenditures. The company primarily generates revenue from grants, collaborations, and licensing agreements.
Year-over-Year Financial Performance: Revenue has been fluctuating in recent years, primarily due to the timing of collaboration agreements and grant funding. The company's net loss has also been increasing due to continued research and development expenses.
Cash Flow and Balance Sheet: Genprex is primarily funded by equity offerings and debt financing. The company has sufficient cash reserves to fund its current operations and ongoing clinical trials.
Dividends and Shareholder Returns
Dividend History: Genprex does not currently pay dividends.
Shareholder Returns: GNPX stock has been volatile in recent years, reflecting the company's early-stage development and the inherent risk associated with pre-revenue biotech companies.
Growth Trajectory
Historical Growth: Genprex has experienced significant growth in recent years, primarily driven by collaborations and grant funding.
Future Growth Projections: The company's future growth depends on the success of its clinical trials and potential regulatory approvals. If successful, the commercialization of the Oncoprex platform could drive significant revenue growth and shareholder value.
Recent Product Launches and Strategic Initiatives: Genprex is actively pursuing the development of its Oncoprex platform and exploring new partnerships and collaborations.
Market Dynamics
Industry Trends: The gene therapy market is rapidly evolving, with significant advancements in technology and growing interest from pharmaceutical companies. The market is expected to be driven by increasing demand for personalized medicine and the potential for gene therapy to treat a wide range of diseases.
Genprex's Market Position: Genprex is a relatively small player in the gene therapy market but has a potentially differentiated technology with its Oncoprex platform. The company's success will depend on its ability to execute its clinical trials successfully and obtain regulatory approvals.
Competitors
- Oncolytics Biotech Inc. (ONCY): Market cap: $120 million, focuses on developing oncolytic virus therapies for cancer.
- Adverum Biotechnologies Inc. (ADVM): Market cap: $150 million, develops gene therapy products for the treatment of rare diseases.
- Castle Creek Pharmaceuticals Inc. (NTLA): Market cap: $140 million, specializes in CRISPR-based gene editing technologies.
Potential Challenges and Opportunities
Key Challenges:
- Successful completion of ongoing clinical trials and regulatory approvals.
- Competition from established players in the gene therapy market.
- Maintaining sufficient funding for research and development.
Potential Opportunities:
- Success of the Oncoprex platform in clinical trials and potential commercialization.
- Expanding partnerships and collaborations with pharmaceutical companies.
- Leveraging technological advancements in gene therapy to develop new products.
Recent Acquisitions (last 3 years)
Genprex has not made any acquisitions in the last three years.
AI-Based Fundamental Rating
Based on an AI-based analysis of Genprex's fundamentals, the company receives a rating of 6 out of 10. This rating considers the company's financial health, market position, future prospects, and potential risks.
Justification: Genprex has a promising technology platform with the potential to disrupt the cancer immunotherapy market. However, the company is still in the early stages of development and faces significant challenges in bringing its product to market.
Sources and Disclaimers
Sources:
- Genprex Inc. website (www.genprex.com)
- SEC filings
- Bloomberg
- Yahoo Finance
Disclaimer: This overview is based on publicly available information and does not constitute financial advice. Investors should conduct their own due diligence before making any investment decisions.
About NVIDIA Corporation
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2018-03-29 | President, CEO, CFO & Director Mr. Ryan M. Confer M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 21 | Website https://www.genprex.com |
Full time employees 21 | Website https://www.genprex.com | ||
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.